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Background: There is concern that artesunate resistance is developing in Southeast Asia. The purpose of this study
is to investigate the prevalence of parasitaemia in the few days following treatment with artesunate-mefloquine
(AM), which is an indirect measure of decreased artesunate susceptibility.
Methods: This is a retrospective analysis of 31 therapeutic efficacy studies involving 1,327 patients treated with AM
conducted by the Thai National Malaria Control Programme from 1997–2007.
Results: The prevalence of patients with parasitaemia on day 2 was higher in the east compared to the west
(east: 20%, west: 9%, OR 2.47, 95% CI: 1.77, 3.45). In addition, the prevalence of day-2 parasitaemia increased over
time (OR for each year = 1.10, 95% CI: 1.03, 1.19). After controlling for initial parasitaemia and age, year and region
remained important determinants of day-2 parasitaemia (OR for region = 3.98, 95%CI 2.63, 6.00; OR for year = 1.28,
95%CI: 1.17, 1.39). The presence of parasitaemia on day 2 and day 3 were specific, but not sensitive predictors of
treatment failure.
Discussion: Delayed resolution of parasitaemia after AM treatment increased in eastern Thailand between 1997 and
2007, which may be an early manifestation of decreased artesunate susceptibility. However, clinical and
parasitological treatment failure after 28 days (which is related to both mefloquine and artesunate decreased
susceptibility) is not changing over time. The presence of parasitaemia on day 2 is a poor indicator of AM 28-day
treatment failure.
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Artemisinin combination therapy (ACT) is the first-line
treatment for uncomplicated falciparum malaria in most
of the world [1]. As a result, the emergence of artemisinin
resistance would have worldwide implications. Southeast
Asia has been the focus of monitoring for artemisinin
resistance, as these compounds were first used as mono-
therapy in Vietnam over two decades ago and later in
Thailand and Cambodia in combination with mefloquine
[2–4]. In addition, the Thai-Cambodian border has a
long history of anti-malarial resistance, as chloroquine,* Correspondence: satimaiw@yahoo.co.th
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emerged here [5,6].
In most of Thailand today, uncomplicated falciparum
malaria is treated with artesunate-mefloquine (AM) [7].
This drug combination was first introduced in 1994 and
it was adopted nationwide in 2005. This combination is
also used in the surrounding countries of Cambodia and
Myanmar [7].
Along the Thai-Cambodian border, AM efficacy has
been declining, with 42-day parasitological cure rates of
79-83% [8–10]. AM appears more efficacious near the
Thai-Myanmar border, with 42-day parasitological cure
rates of >90% [9,11]. However, a recent report suggests
efficacy may be starting to decrease in this area as well
[12]. Since combination therapy was used in these trials,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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worsening mefloquine resistance, development of artesu-
nate resistance, or both.
Though not an ideal approach, measuring parasite
clearance time (PCT) is one way to help differentiating
artesunate from mefloquine resistance in trials of AM.
PCT is the time it takes for the parasitaemia to clear
after anti-malarial treatment. PCT is more strongly
determined by artesunate than mefloquine due to arte-
sunate’s quick onset of action [13–17]. Therefore, a pro-
longed PCT would suggest increasing artesunate
resistance. A recent study suggested that monitoring the
presence of day-3 parasitaemia is a useful predictor of
42-day recrudescence after taking AM [18]. Based on
The World Health Organization (WHO)’s working def-
inition of artemisinin resistance, areas with 10% or
greater prevalence of parasitaemia on day 3 should be
further evaluated especially with a trial of artemisinin
monotherapy [19].
The purpose of this study is to determine if PCT of
AM varies by region and over time in Thailand and to
assess the ability of the presence of parasitaemia on day
2 and day 3 to predict 28 day clinical and parasitological
failure of AM. Because of loss to follow-up, day-2 para-
sitaemia measurement has the potential to be a more
practical surveillance tool.
Methods
Study sites and data collection
Data was used from the therapeutic efficacy studies (TES)
conducted by the Thai Ministry of Public Health between
1997–2007. These drug resistance monitoring sites are
located in the border provinces of Thailand, where mal-
aria is endemic (Figure 1). Of the seven sites, five were
located in western Thailand (Mae Hong Son, Tak, Kan-
chanaburi, Ratchaburi, and Ranong) and the rest are
located in eastern Thailand (Chanthaburi, Trat). Each site
was not necessarily visited every year (Table 1). The
WHO 1996 protocol for TES was followed until 2003,
when the revised WHO protocol was adopted [20–22].
Inclusion criteria included: pure uncomplicated falcip-
arum malaria with asexual parasite density between 500
and 120,000 parasites/μl, five years old and older, axillary
temperature ≥37.5 °C (or history of fever within 24 hours),
and informed consent of the patient/guardian. Pregnant
women and patients with signs of severe disease were
excluded.
Briefly, at enrolment, subjects were administered meflo-
quine 25 mg/kg in divided doses on day 0 and artesunate
12 mg/kg divided between days 0 and 1. The maximum
artesunate dose was 600 mg and for mefloquine it was
1,250 mg. This two-day regimen, as opposed to the
WHO-recommended three-day regimen, was according
to the standard treatment guidelines for uncomplicatedfalciparum malaria of the Thai National Malaria Control
Programme during the study period. All drug administra-
tion was observed and repeated if there was vomiting
within 30 min.
Asexual parasite density was measured using Giemsa-
stained thick blood films on days 0, 2, 3, 7, 14, 21, and
28 days after enrolment. Seven additional trials extended
the follow-up for 42 days. For these trials, parasite dens-
ity was also measured on days 35 and 42.
Treatment outcome was defined according to the
WHO protocol [20,21]. Because the trials differed in
their length of follow-up (28–42 days), treatment out-
come at day 28 was used so the trials could be com-
pared. Of note, the definition of treatment outcome
slightly differs between the 1996 and 2003 WHO guide-
lines. Therefore, the subjects from the earlier studies
were reclassified in accordance to the 2003 guidelines.
Briefly, the 2003 guidelines define treatment outcome as
follows: Early treatment failure is the development of se-
vere malaria on days 1, 2, or 3 in the presence of parasit-
aemia, day-2 parasitaemia higher than day 0, day-3
parasitaema greater or equal than 25% of the day 0
count, or the presence of parasitaemia on day 3 and with
an axillary temperature greater or equal to 37.5 °C. Late
treatment failure (which combines both late clinical and
late parasitological failure) is the development of severe
malaria after day 3, the presence of parasitaemia and
fever after day 3, or the presence of parasitaemia after
day 7 irrespective of temperature. Adequate clinical and
parasitological response (ACPR) is the absence of para-
sitaemia on day 28 and not meeting the criteria for early
or late treatment failure.
There was no PCR correction of the samples with
positive parasitaemia and therefore re-infections and re-
crudescence could not be distinguished.
Data analysis
The main questions being addressed in the analysis are:
1) does the presence of parasitaemia on day 2 and/or
day 3 predict treatment failure? 2) Do the sites with
higher rates of day-2 and −3 parasitaemia have higher
rates of treatment failure as well? 3) How does day-2
and −3 parasitaemia vary by region and over time?
Treatment failure is defined as either early or late treat-
ment failure according to the WHO guidelines [21]. The
presence of day-2 (or day-3) parasitemia is defined as
the presence of peripheral parasites as detected by thick
smear on day-2 (or day-3).
Chi-square, t-tests, and linear regression were used to
explore the relationship between covariates and region
and time. Age and parasite density were natural loga-
rithm (ln)-transformed to meet the assumption of nor-
mality in the univariate analyses. Logistic regression was
used to examine the association between the presence of
Table 1 Sample sizes for in vivo efficacy studies of mefloquine 25 mg/kg+ artesunate 12 mg/kg
Region Site Year
1997 1998 2002 2003 2004 2005 2006 2007 Ref
West Mae Hong Son 103 189
West Tak 36 41 68 45 32 23 30 [32,33]
West Kanchanaburi 32 38
West Ratchaburi 81 57
West Ranong 37 43 7 14 59
East Chanthaburi 33 44 4 6 3 [33]
East Trat 53 37 72 44 15 20 31 30 [33]
Total 89 37 146 193 103 281 317 157
Chanthaburi
Trat
Tak
Ranong
Kanchanaburi
Ratchaburi
Mae Hong Son
Myanmar
Laos
Cambodia
Thailand
Figure 1 The provinces where in vivo efficacy studies took place in Thailand between 1997–2007.
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and initial parasitaemia were included in the model a
priori to control for potential confounding: both factors
had the potential to vary at the different sites and over
time and both have been associated with PCT (though
an association between PCT and initial parasitemia is
more consistently found than that between PCT with
age) [17,18].
Both age and parasitaemia were coded as categorical
variables with three levels while year was coded as a
continuous variable. These coding decisions were made
so that the variable would best reflect the relationship of
the variable with the presence of day-2 and day-3 para-
sitaemia while taking in account the precision of the es-
timate. Since age was missing from all the subjects in
Tak in 2006, multiple imputation was done with age to
prevent this site from being excluded in the final model.
Briefly, a regression model with initial parasite density,
weight, sex, and region as the covariates was used to
predict the age of the individuals with missing informa-
tion on age.
A sensitivity analysis was done to explore the effect of
outcome misclassification on the calculation of the sen-
sitivity and specificity of the presence of day-2 parasit-
aemia as a marker of treatment failure. This outcome
misclassification was assumed to be non-differential with
regard to day-2 parasitaemia. Corrected sensitivity and
specificity estimates of the presence of day-2 parasit-
aemia as an indicator of treatment failure were calcu-
lated using estimates of sensitivity and specificity of the
28-day uncorrected outcome as a measure of 42-day
PCR-corrected outcome [23–26]. These estimates were
derived from the literature. Three studies were found that
met the following criteria: 1) took place in the Greater
Mekong sub-region; 2) subjects received mefloquineTable 2 General characteristics of the participants for in vivo
Total
Age mean (95% CI) 31.6 (30.8, 32.3)
range (5, 80)
missing 61
Weight (kg) mean (95% CI) 52.9 (52.3, 53.5)
range (15, 92)
missing 223
Initial parasite geometric mean (95% CI) 17998 (16861, 19135)
density range (520, 116960)
missing 0
Sex male (%) 1071 (81.1)
female (%) 249 (18.9)
missing 7
Abbreviations: OR, odds ratio; CI, confidence interval.
*Results of t-tests (age, weight, and initial parasite density) and chi-square test (sex)25 mg/kg and artesunate 12 mg/kg; and, 3) provided
enough detail to derive sensitivity and specificity estimates
[23,24,27].
All statistical analyses were done in Stata 11.1.
These studies were approved by the Ethical Committee
for Research in Humans of the Thai Ministry of Public
Health. Institutional Review Board at UNC Chapel Hill
approved secondary analysis of this dataset.
Results
General characteristics
In total, 1,327 subjects from 31 TES at seven different
sites spanning 11 years were included in this analysis
(Table 1). The subjects in the east were older, had high-
est initial parasite density, and were more often male
(Table 2). Age was missing from 61 subjects, including
all the subjects at Tak in 2006. The mean age slightly
decreased over time (linear regression of natural loga-
rithm (age): β =− 0.018, t = 3.73, p < 0.001). Initial para-
site density also slightly decreased over time (linear
regression of natural logarithm (initial parasitaemia) and
year: β = −0.026, t = 2.11, p = 0.035).
Overall, 6.5% of the subjects experienced treatment
failure by 28 days (82/1260). Sixty-seven subjects were
lost to follow-up. Twenty-eight-day treatment failure
varied by site (ANOVA, F = 3.85, df = 6 p < 0.001;
Figure 2). Overall, treatment failure was higher in the
east (34/379, 9.0%) than west (48/881, 5.5%; Chi-
square = 5.40, p = 0.020). There was no change in treat-
ment failure over time (linear regression, β=− 0.003, 95%
CI: -0.008, 0.002). When controlling for age and initial
parasite density, treatment failure remained higher in
the east and there was still no change over time (region:
OR= 1.92, 95%CI: 1.12, 3.31; year: OR= 1.01, 95%CI:
0.92, 1.11).efficacy studies by region
East West p-value*
35.2 (33.9, 36.5) 30.0 (29.1, 30.9) p < 0.001
(8, 74) (5, 80)
7 54
55.2 (53.9, 56.4) 52.3 (51.6, 53.0) p < 0.001
(18, 85) (15, 92)
164 59
20478 (18189, 22766) 16958 (15663, 18253) p = 0.007
(560, 116000) (520, 116960)
0 0
334 (85.2) 737 (79.4) p = 0.014
58 (14.8) 191 (20.6)
0 7
. Both age and parasite density was natural logarithm transformed.
Figure 2 28-day treatment failure over time in Thailand 1997–2007. Chanthaburi and Trat are in the east, the rest of the sites are in the
west.
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parasitaemia
Data on presence of day-2 and day-3 parasitaemia were
available for over 99% of the subjects (day 2: 1325/1327,
day 3: 1321/1327). The presence of day-2 and −3 parasit-
aemia varied substantially by site (ANOVA, day 2:
F = 13.46, df = 6, p < 0.001; day 3: F = 6.31, df = 6,
p < 0.001; Figure 3). The presence of parasitaemia on
days 2 and 3 were more common in the east than the
west (day 2: east: 20%, west: 9%, OR 2.47, 95% CI: 1.77,
3.45; day 3: east: 7%, west: 3%, OR = 2.79, 95%CI: 1.60,
4.87). The odds of day-2 parasitaemia increased on
average 10% per year (OR = 1.10, 95% CI: 1.03, 1.19;
Table 3). The increase for day 3 was similar, though the
estimate was less precise (OR = 1.12, 95% CI: 0.98, 1.27;
Table 4).
When controlling for age and initial parasitaemia, re-
gion and year remained associated with the presence of
parasitaemia on day 2 (Table 3). Unfortunately, site
could not be controlled for in the multivariable analysis,
as the variable caused substantial collinearity with re-
gion in the logistic regression model. When the analysis
was restricted to Trat (east), Tak (west), and Ranong
(west), which were the sites most consistently sampled
over time, the results did not substantially differ from
those shown in Table 3 (in adjusted analysis of day-2
parasitemia: OR for region = 2.88, 95%CI 1.78, 4.65; OR
for year = 1.35, 95%CI: 1.23, 1.49). This suggests that dif-
ferent sites being sampled at each year did not influencethe results. These analyses were repeated for the pres-
ence of day-3 parasitaemia and the trends were similar,
though the estimates were less precise (Table 4).
Day-2 and -3 parasitaemia and treatment failure
Overall, 12% of the subjects were parasitaemic on day 2
(161/1,325) and 4% were parasitaemic on day 3 (51/
1,321). Of the 51 subjects parasitaemic on day 3, 49 were
also parasitaemic on day 2. Both day-2 and −3 positivity
were independent predictors of 28-day treatment failure
in individuals when controlling for age and initial para-
sitaemia (day 2: OR= 2.82, 95%CI: 1.64, 4.86; day 3:
OR= 4.16, 95%CI: 1.97, 8.78). Removing subjects who
experience early treatment failure decreased the magni-
tude of effect (day 2: OR= 2.26, 95%CI: 1.26, 4.04 day 3:
OR= 2.50 95%CI: 1.01, 6.16).
Both day-2 and −3 positivity were a specific predictor
for 28-day treatment failure (day 2: 1042/1177 = 88.5%,
95%CI 86.6, 90.3; day 3: 1138/1178 = 96.6%, 95%CI 95.4,
97.6). However, both had poor sensitivity (day 2: 21/
81 = 25.9, 95%CI 16.8, 36.9; day 3: 10/81 = 12.4, 95%CI:
6.1, 21.5). There was no statistical significant differences
between the areas under the ROC curves for day-2 and
day-3 (day 2: 0.572 day 3: 0.545; chi-square 1.65,
p = 0.199).
The positive predictive value (PPV) was low for both
day-2 and day-3 parasitaemia prevalence (day 2: 13.5,
95%CI: 8.5, 19.8; day 3: 20.0, 95%CI: 10.0, 33.7). When
extrapolated for different prevalences of treatment
Table 3 Factors associated with the presence of day-2 parasitaemia after treatment with mefloquine and artesunate
12 mg/kg*
Variable Level Day-2 parasitaemia (n) Univariate Multivariable
yes no OR 95% CI OR 95% CI
Region East 77 315 2.47 (1.77, 3.45) 4.10 (2.75, 6.12)
West 84 849 1.† 1.
Year 1997 2 86 1.10{ (1.03, 1.19) 1.27 (1.17, 1.38)
1998 0 37
2002 15 130
2003 31 162
2004 17 90
2005 51 230
2006 17 300
2007 28 129
Age ≤18 22 213 1. 1.
19-29 81 585 1.34 (0.82, 2.20) 1.33 (0.80, 2.20)
≥30 49 314 1.51 (0.89, 2.57) 1.29 (0.73, 2.28)
Parasitaemia <10000 56 608 1. 1.
(parasites/μl) 10000-50000 83 466 1.93 (1.34, 2.77) 2.02 (1.39, 2.93)
>50000 22 90 2.65 (1.54, 4.56) 2.70 (1.53, 4.74)
Abbreviations: OR, odds ratio; CI, confidence interval.
*Results from both univariate and multivariable logistic regression are presented. Multiple imputation was used for age in the multivariable but not the univariate
analyses.
†reference level.
{Year was coded as a continuous variable so the OR represents the comparison per one year increase in time.
Figure 3 Day-2 and day-3 parasitaemia over time in Thailand 1997–2007. Chanthaburi and Trat are in the east, the rest of the sites are in
the west.
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Table 4 Factors associated with the presence of day-3 parasitaemia after treatment with mefloquine and artesunate
12 mg/kg*
Variable Level Day-3 parasitaemia (n) Univariate Multivariable
yes no OR 95% CI OR 95% CI
Region East 27 365 2.79 (1.59, 4.90) 4.69 (2.48, 8.88)
West 24 905 1.† 1.
Year 1997 0 89 1.12{ (0.98, 1.27) 1.29 (1.12, 1.49)
1998 0 37
2002 5 140
2003 9 180
2004 10 97
2005 9 272
2006 9 307
2007 9 148
Age ≤18 4 229 1. 1.
19-29 31 635 2.79 (0.98, 8.00) 2.43 (0.84, 7.02)
≥30 14 348 2.30 (0.75, 7.08) 1.60 (0.50, 5.14)
Parasitaemia <10000 21 641 1. 1.
(parasites/μl) 10000-50000 26 522 1.52 (0.85, 2.73) 1.53 (0.84, 2.79)
>50000 4 107 1.14 (0.38, 3.39) 1.04 (1.34, 3.19)
Abbreviations: OR, odds ratio; CI, confidence interval.
*Results from both univariate and multivariable logistic regression are presented. Multiple imputation was used for age in the multivariable but not the univariate
analyses.
†reference level.
{Year was coded as a continuous variable so the OR represents the comparison per one year increase in time.
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ment failure was less than 20% (Figure 4). Thus, both
day-2 and day-3 parasitaemia predict treatment failure
with similar high levels of specificity and low levels of
sensitivity.
Using day 2 as a proxy for treatment failure would
misclassify 60 patients that experienced treatment failure
as ACPR (which is 74% of all the treatment failures).
Day 3 would lead to misclassifying 71 treatment failuresFigure 4 Extrapolated positive predictive values (PPVs) and
negative predictive values (NPVs). Based on the relationship
between day-2 parasitaemia and 28-day treatment failure.as ACPR (which is 87% of all treatment failures). Day 2
would misclassify 135 patients and day 3 would misclas-
sify 40 patients as treatment failures when they were
ACPR, which is 11% and 3% of the total ACPR, respect-
ively. This suggests that day 2 and day 3 are equivalent
to each other and that neither are good indicators for
28-day treatment failure.
A simple sensitivity analysis was done to explore the
effect of outcome misclassification on the relationship
between the presence of day-2 parasitaemia and treat-
ment failure. When taking account for outcome mis-
classification (based on estimates of sensitivity and
specificity for 28-day PCR-uncorrected as a proxy for
42-day PCR-corrected treatment failure derived from
three separate studies), there was little difference in the
sensitivity and specificity estimates of day-2 parasitaemia
as an indicator for treatment failure (Table 5). Therefore,
the fact that this study used the suboptimal measure of
treatment failure of 28-day PCR-uncorrected treatment
failure did not greatly influence the results.
When individual sites were compared, the percentage
of subjects with either day-2 or day-3 parasitaemia
showed a non-significant trend to increasing with the
level of treatment failure found at that site (linear re-
gression, day 2: β=0.76, 95%CI: -0.34, 0.49; day 3:
β=0.73, 95%CI: -0.08, 1.55; Figure 5).
Table 5 Sensitivity analysis of outcome misclassification*
Uncorrected Alker
2007
Hutagalung
2005
Rogers
2009
Sensitivity 25.9 22.6 15.1 15.4
Specificity 88.5 95.0 94.6 95.1
PPV 13.5 27.8 24.2 34.3
NPV 94.6 93.4 90.6 87.0
Abbreviations: PPV positive predictive value, NPV negative predictive value.
*The uncorrected estimates are from this study. The relationship between
day-28 PCR-uncorrected treatment failure and 42-day PCR-corrected treatment
failure from three different studies was used to calculate the sensitivity,
specificity, PPV, and NPV of day-2 parasitaemia as an indicator of 42-day
PCR-corrected treatment failure.
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This pooled analysis from seven geographically dispersed
surveillance sites in Thailand demonstrates that parasite
clearance time after AM has increased between 1997
and 2007. In particular, Trat, near the Cambodian border
has had a dramatic increase: the prevalence of parasit-
aemia on day 2 was 0% in 1997 and steadily increased to
43% in 2007. In comparison, in Tak, near the Burma
border, the prevalence of delayed parasite clearance has
mostly been under 10%. Of note, both initial parasite
density and age changed by region and time, which may
be due to differences in endemicity, environmental fac-
tors, demographics or possibly due to changing migra-
tion patterns. After controlling for these factors, day-2
parasitaemia was still increasing over time and remained
higher in the east.
A previous study of a refugees’ camp in Tak in western
Thailand demonstrated an increase in the prevalence of
day-2 parasitaemia after AM from 3.6 to 15% from
1995–2007, which is smaller than reported here [11].
The difference is likely due to site-to-site variability and
alterations in how the study drugs were given. However,Figure 5 The percentage of subjects who were parasitaemic
and the 28-day treatment failure.this is still much lower than the prevalence of day-2
parasitaemia reported here for eastern Thailand. A small
study in Pailin, Cambodia found that artesunate mono-
therapy had a longer parasite clearance time and a
higher recrudescence rate compared in Wang Pha, in
north-west Thailand [28]. However, the small sample
size, the differences in baseline characteristics between
the groups and technical issues in outcome determin-
ation make this study difficult to interpret [29]. Lastly,
Phyo et al. recently reported an increase in the parasite
clearance half-lives along the northwestern border of
Thailand, with the largest increase occurring between
2008 and 2010 [30].
While it is clear that the prevalence of parasitaemia on
days 2 and 3 are increasing and are higher in the east,
the significance of this finding is more difficult to inter-
pret. The presence of parasitaemia on days 2 and 3 are
predictive of AM treatment failure in individuals but
they have poor sensitivity and positive predictive value.
However, parasitaemia on days 2 and 3 do have high
negative predictive value. Therefore, the lack of parasit-
aemia on days 2 and 3 implies the person has a good
chance of achieving adequate clinical and parasitological
response to the treatment. However, the presence of
parasitaemia is less informative.
In addition, the prevalence of parasitaemia on days 2
or 3 was not related to the overall treatment failure rate.
While parasitaemia on day 2 is increasing over time,
treatment failure rates are relatively constant. This lack
of an association could be explained by delayed parasite
clearance being not the best indicator of treatment fail-
ure. Another possibility is that delayed parasite clearance
time is an early indicator of the emergence of artesunate
resistance, which is not yet affecting the treatment fail-
ure rates.
The disconnect between day-2 and day-3 parasitaemia
and treatment failure may also be due to mefloquine re-
sistance being the main factor influencing treatment fail-
ure but having only a minor impact on parasite
clearance rates. Using molecular markers of mefloquine
resistance (such as pfmdr1 genotype and copy number)
may be a way to distinguish between mefloquine and
artesunate decreased susceptibility and also would im-
prove predictions of treatment failure.
When comparing day-2 and day-3 parasitaemia preva-
lence, there is little difference in their ability to predict
AM treatment outcome. Day 2 and 3 had similar nega-
tive predictive ability but day 3 had slightly higher posi-
tive predictive power, which is consistent with previous
studies [18]. ROC analysis suggests that neither are ad-
equate surveillance tools for AM treatment failure.
The outcome in this analysis (28-day treatment failure)
is suboptimal, as it is prone to misclassification as treat-
ment failure can occur after this time period. However, a
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this outcome has little influence of the results. In
addition, the sensitivity and specificity reported here are
similar to those calculated with a more stringent out-
come measurement [18].
Also of note, no PCR-correction was done for the
patients with recurrent parasitaemia. However, malaria
incidence is generally low in most of the Mekong Sub-
region, especially in Thailand. The majority of cases are
occupationally exposed during a jungle trip, which typic-
ally lasts over a week. Therefore, patients who were suc-
cessfully followed-up weekly in these studies were
unlikely to get re-exposed to malaria in the jungles. The
effect of PCR correction on the magnitude of the treat-
ment outcomes was shown to be negligible in a similar,
occupationally-exposed population of south-western
Cambodia [23].
The main strength of this analysis is that this is the
most extensive description of parasite clearance time fol-
lowing ACT reported to date, encompassing multiple
sites throughout Thailand over 10 years. The main lim-
itations are that because these data were generated from
the routine drug resistance monitoring system of a na-
tional malaria control programme, metabolites for arte-
sunate were not measured. Therefore suboptimal drug
levels causing the increasing prevalence of parasites on
days 2 and 3 could not be ruled out. In addition, haemo-
globin E strongly influences parasite clearance time [31]
and therefore geographic variations in genotype could
cause the regional differences in day-2 and −3 parasit-
aemia seen in this study. However, haemoglobin E geno-
types cannot explain the increasing day-2 and −3
parasitaemia over time in the absence of massive popula-
tion migration.
The presence of parasites on day 2 is more readily
measured than on day 3, as often patients return any
way on day 2 for directly observed therapy. Returning
again on day 3 increases the cost of in vivo studies (due
to incentives) without much benefit. Both day 2 and day
3 have poor sensitivity for treatment failure in indivi-
duals, as has been seen previously [18]. The positive pre-
dictive value is low when the prevalence of treatment
failure rate is less than 20%. Since the WHO recom-
mends a treatment regimen be changed prior to it reach-
ing that level of treatment failure, day-2 and −3
parasitaemia may not be useful on its own. In addition,
this study implies that day-2 parasitaemia cannot be
used as a way to detect sites with high treatment failure
rates. However, day-2 parasitaemia may be a way to in-
crease the efficiency of surveillance for treatment failures
in resource-limited areas. For example, patients that re-
main parasitaemic on day 2 should be closely followed
for treatment failure. Patients who cleared their parasites
early have a much lower risk of treatment failure, andtherefore could be followed more passively. Similar data
evaluating day-2 and day-3 parasitaemia prevalence and
its association with subsequent treatment data may be
available from other sites of routine TES monitoring and
could be mined to further evaluate the usefulness of and
limitations of these proxy measures.
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